Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company will engage in a fireside chat scheduled for June 5, 2025, from 11:05 to 11:35 AM ET. The presentation will be accessible via webcast and will remain available for replay on Compass' Events page for 90 days following the event.
Compass Therapeutics (NASDAQ: CMPX), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie oncologiche basate su anticorpi, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. La società parteciperà a una tavola rotonda informale programmata per il 5 giugno 2025, dalle 11:05 alle 11:35 ET. La presentazione sarà disponibile in diretta streaming e potrà essere rivista nella pagina Eventi di Compass per 90 giorni dopo l'evento.
Compass Therapeutics (NASDAQ: CMPX), una empresa biofarmacéutica en etapa clínica enfocada en el desarrollo de terapias contra el cáncer basadas en anticuerpos, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. La compañía participará en una charla informal programada para el 5 de junio de 2025, de 11:05 a 11:35 AM ET. La presentación estará disponible vía webcast y podrá ser reproducida en la página de Eventos de Compass durante 90 días después del evento.
Compass Therapeutics (NASDAQ: CMPX)는 항체 기반 암 치료제 개발에 주력하는 임상 단계 바이오제약 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여할 예정임을 발표했습니다. 회사는 2025년 6월 5일 오전 11시 05분부터 11시 35분(동부시간)까지 예정된 화상 대화에 참여할 것입니다. 발표는 웹캐스트를 통해 시청 가능하며, 행사 후 90일간 Compass 이벤트 페이지에서 다시보기로 제공됩니다.
Compass Therapeutics (NASDAQ : CMPX), une société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies anticorps contre le cancer, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. La société prendra part à une discussion informelle prévue le 5 juin 2025, de 11h05 à 11h35 (heure de l'Est). La présentation sera accessible en webcast et restera disponible en replay sur la page Événements de Compass pendant 90 jours après l'événement.
Compass Therapeutics (NASDAQ: CMPX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Antikörper-basierten Krebstherapeutika spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference bekannt gegeben. Das Unternehmen wird an einem Fireside-Chat teilnehmen, der für den 5. Juni 2025, von 11:05 bis 11:35 Uhr ET geplant ist. Die Präsentation wird per Webcast verfügbar sein und kann auf der Veranstaltungsseite von Compass für 90 Tage nach der Veranstaltung erneut angesehen werden.
- None.
- None.
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025.
Fireside Chat Details
Date: Thursday, June 5, 2025
Time: 11:05 – 11:35 AM ET
Webcast Link: https://wsw.com/webcast/jeff319/cmpx/1867328
Virtual/Replay availability: The fireside chat will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
FAQ
When is Compass Therapeutics (CMPX) presenting at the Jefferies Global Healthcare Conference 2025?
How long will the CMPX fireside chat replay be available?
What type of company is Compass Therapeutics (CMPX)?
Where can I watch Compass Therapeutics' (CMPX) Jefferies conference presentation?
